Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1480516 | 1.00 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1MAPTAVPR1BCNR1 | |
| SCHEMBL1481636 | 0.90 | MAPT (0.43) | CYSLTR2CYSLTR1MAPTCNR1CYP1A2 | |
| SCHEMBL1481638 | 0.90 | MAPT (0.43) | CYSLTR2CYSLTR1MAPTCNR1CYP1A2 | |
| SCHEMBL1481004 | 0.90 | MAPT (0.38) | CYSLTR2CYSLTR1MAPTAVPR1BCNR1 | |
| SCHEMBL1481006 | 0.90 | MAPT (0.38) | CYSLTR2CYSLTR1MAPTAVPR1BCNR1 | |
| SCHEMBL1480600 | 0.89 | MAPT (0.41) | CYSLTR2CYSLTR1MAPTAVPR1BCNR1 | |
| SCHEMBL1481707 | 0.89 | MAPT (0.41) | CYSLTR2CYSLTR1MAPTAVPR1BCNR1 | |
| SCHEMBL1481302 | 0.89 | MAPT (0.39) | CYSLTR2CYSLTR1MAPTAVPR1BCNR1 | |
| SCHEMBL1480640 | 0.89 | MAPT (0.39) | CYSLTR2CYSLTR1MAPTAVPR1BCNR1 | |
| SCHEMBL1481305 | 0.89 | MAPT (0.39) | CYSLTR2CYSLTR1MAPTAVPR1BCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004071447-A9 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | CYSLTR2 2986/4885CYSLTR1 2945/4885MAPT 3558/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | CYSLTR2 2986/4885CYSLTR1 2945/4885MAPT 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.